Real-world clinical outcomes in metastatic breast cancer patients treated with palbociclib
PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer
Is there a use for palbociclib in the treatment of pancreatic neuroendocrine tumors?
What have we learned from recent clinical trials in early breast cancer treatment?
Understanding resistance to combined BRAF and MEK inhibiton in melanoma and the significance of CDK4